MIFEPREX® Label MIFEPREX® (mifepristone) Tablets, 200 mg For Oral Administration Only DOSAGE AND ADMINISTRATION Treatment with Mifeprex and misoprostol for the termination of pregnancy requires three office visits by the patient. Mifeprex should be prescribed only by physicians who have read and understood the prescribing information. Mifeprex may be administered only in a clinic, medical office, or hospital, by or under the supervision of a physician, able to assess the gestational age of an embryo and to diagnose ectopic pregnancies. Physicians must also be able to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have made plans to provide such care through others, and be able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary. Day One: Mifeprex Administration Patients must read the MEDICATION GUIDE and read and sign the PATIENT AGREEMENT before Mifeprex is administered. Three 200 mg tablets (600 mg) of Mifeprex are taken in a single oral dose. Day Three: Misoprostol Administration The patient returns to the health care provider two days after ingesting Mifeprex. Unless abortion has occurred and has been confirmed by clinical examination or ultrasonographic scan, the patient takes two 200 μg tablets (400 μg) of misoprostol oral y. During the period immediately following the administration of misoprostol, the patient may need medication for cramps or gastrointestinal symptoms (see ADVERSE REACTIONS). The patient should be given instructions on what to do if significant discomfort, excessive vaginal bleeding or other adverse reactions occur and should be given a phone number to call if she has questions following the administration of the misoprostol. In addition, the name and phone number of the physician who will be handling emergencies should be provided to the patient. Day 14: Post-Treatment Examination Patients will return for a follow-up visit approximately 14 days after the administration of Mifeprex. This visit is very important to confirm by clinical examination or ultrasonographic scan that a complete termination of pregnancy has occurred. According to data from the U.S. and French studies, women should expect to experience vaginal bleeding or spotting for an average of nine to 16 days. Up to 8% of women may experience some type of bleeding for more than 30 days. Persistence of heavy or moderate vaginal bleeding at this visit, however, could indicate an incomplete abortion. Patients who have an ongoing pregnancy at this visit have a risk of fetal malformation resulting from the treatment. Surgical termination is recommended to manage medical abortion treatment failures (see PRECAUTIONS, Pregnancy). Adverse events, such as hospitalization, blood transfusion, ongoing pregnancy, or other major complications following the use of Mifeprex and misoprostol must be reported to Danco Laboratories. Please provide a brief clinical and administrative synopsis of any such adverse events in writing to: Medical Director Danco Laboratories, LLC P.O. Box 4816 New York, NY 10185 1-877-4-Early Option (1-877-432-7596)
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020687s013lbl.pdf
Reprint Article From “The Pink Sheet” “The Pink Sheet” Prescription Pharmaceuticals & Biotechnology GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become
Warfarin reversal – Emergent Surgery or Invasive Procedure and INR ≥ 2 Authors: Colleen Morton MD, David Dries MD, Gary Collins MD, Michael McGonigal MD Approved: 2/4/2014 PURPOSE: To provide guidelines for reversal of Warfarin in a patient who needs an emergent surgery or invasive procedure and has an INR ≥ 2. Kcentra (prothrombin complex concentrate, contains plasma-derived F